Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Journal: Nature Medicine

Published: 2018-08-06

DOI: 10.1038/s41591-018-0134-3

Affiliations: 7

Authors: 22

Go to article
Institutions FC
Genentech, Inc., United States of America (USA) 0.55
Foundation Medicine, Inc., United States of America (USA) 0.27
UC Davis Comprehensive Cancer Center, United States of America (USA) 0.05
Lungenfachklinik Immenhausen, Germany 0.05
Kaiser Permanente Vallejo Medical Center, United States of America (USA) 0.05
State Key Laboratory in Oncology in South China, CUHK, China 0.02
Department of Clinical Oncology, PWH CUHK, China 0.02

Return